Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Silence Therapeutics ( (SLN) ) has provided an announcement.
On October 23, 2025, Silence Therapeutics announced the completion of patient enrollment in the SANRECO Phase 2 study of divesiran for treating polycythemia vera (PV). This milestone reflects the growing interest in divesiran, a first-in-class siRNA targeting TMPRSS6, which aims to maintain hematocrit levels below 45% without phlebotomies. The study’s results are expected in the third quarter of 2026, potentially impacting the treatment landscape for PV, a condition with significant unmet needs.
The most recent analyst rating on (SLN) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Silence Therapeutics stock, see the SLN Stock Forecast page.
Spark’s Take on SLN Stock
According to Spark, TipRanks’ AI Analyst, SLN is a Neutral.
The overall score is primarily driven by strong technical indicators suggesting bullish momentum. However, financial performance and valuation concerns, such as profitability challenges and negative equity, weigh down the score.
To see Spark’s full report on SLN stock, click here.
More about Silence Therapeutics
Silence Therapeutics is a global clinical-stage biotechnology company specializing in precision-engineered medicines using proprietary siRNA technology. The company focuses on addressing high unmet medical needs in areas such as cardiovascular disease, hematology, and rare diseases.
Average Trading Volume: 88,186
Technical Sentiment Signal: Hold
Current Market Cap: $349.5M
Learn more about SLN stock on TipRanks’ Stock Analysis page.